BeiGene's Trading Volume Surges 72% to 2.49 Billion, Ranks 343rd in Daily Volume

On April 1, 2025, BeiGene's trading volume reached 2.49 billion, marking a 72.03% increase from the previous day. This surge placed BeiGene at the 343rd position in the day's trading volume rankings. The company's stock price experienced a slight decline of 0.42%.

BeiGene has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for its drug TEVIMBRA®. This recommendation is for the use of TEVIMBRA® in combination with etoposide and platinum chemotherapy as a first-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC). The approval is based on the results of the RATIONALE-312 study, which demonstrated a statistically significant improvement in overall survival for patients treated with TEVIMBRA® plus chemotherapy compared to those treated with placebo plus chemotherapy.

The study, which involved 457 patients, showed that the median overall survival was 15.5 months for patients receiving TEVIMBRA® with chemotherapy, compared to 13.5 months for those receiving placebo plus chemotherapy. This resulted in a 25% reduction in the risk of death. The combination therapy was generally well tolerated, with no new safety signals identified. The most common Grade 3 or 4 adverse reactions included neutropenia, anemia, thrombocytopenia, and fatigue.

TEVIMBRA® is currently approved in the EU for several indications, including unresectable esophageal squamous cell carcinoma and gastric or gastroesophageal junction adenocarcinoma in combination with chemotherapy, as well as for non-small cell lung cancer in both first- and second-line settings. BeiGene's recent announcement of its intent to change its name to BeOne Medicines reflects its commitment to developing innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible.